Idéal Investisseur
Français English
CAC 40 : Market closed
7 969,42 pts
-0.01%


Last updated : 30/10/2026 - 17h36

OSE IMMUNO news: financial news, earnings, stock moves and analysts

Live news related to OSE IMMUNO stock (FR0012127173): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.

The latest financial news on OSE IMMUNO mainly cover M&A activity, earnings publications et share price moves. The stock trades at €1,95 on Euronext Paris, down 7,31% at the last update. This page lists the articles published on OSE IMMUNO stock to track the share price, company announcements and any item likely to influence market perception.

Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
OSE IMMUNO
FR0012127173
Pharmaceuticals & Biotechnology / Biotechnology
1,95 € -7,31 %
High2,18 €
Low1,95 €
Last update : 30/10/2026 - 17:35:21 – Euronext Paris – 15 min delay.
Market closed

Latest OSE IMMUNO stock news

OSE Immunotherapeutics published on October 29, 2026 the full results of the Combi-TED trial, presented at the annual ESMO congress. They confirm the …

The Nantes biotech company is declining during the session, following its first phase 2 results in lung cancer. The stock is trading below its three m…

OSE Immunotherapeutics unveiled on October 19, 2026 the initial results of the Combi-TED phase 2 trial, through an abstract selected for oral presenta…

The Nantes-based biotech announced, in a press release published on October 15, 2026, the participation of its management at the 10th annual conferenc…

The Nantes-based biotech company published on September 28, 2026 its cash position as of June 30, 2026 and modified its financial calendar. It indicat…

The Nantes-based biotech is rebounding sharply this Wednesday, ranking among the strongest gainers on the CAC All Shares. The rebound comes after the …

The Nantes-based biotech company announced that the primary results of its phase 2 Combi-TED trial, evaluating Tedopi in metastatic non-small cell lun…

Partner Veloxis Pharmaceuticals is conducting this phase 2 trial on a molecule initially discovered and developed by the Nantes-based biotech, then li…

The biotechnology company announced the holding of an online session bringing together international experts on chronic inflammatory bowel diseases (I…

The Nantes-based biotech's stock undergoes a sharp correction during the session, contrary to a significantly bullish Parisian market. This movement c…

Ad
Chaque matin
Les signaux techniques du marché,
avant l'ouverture.
CAC 40 · SBF 120 · Signaux · Analystes
🤖
Édition du jour — avant bourse
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Signaux haussiers
+5,2%
+1,8%
+0,9%
📉 Signaux baissiers
-14%
-5,7%
🔄 Avis analystes
▲ 35 €
▼ 80 €
Inscrivez-vous pour tout voir →
Avant 9h chaque matin
Données Euronext
Analyse automatique IA